Who makes rAAVrh74.MHCK7.DYSF.DV?

rAAVrh74.MHCK7.DYSF.DV is developed by Sarepta Therapeutics, Inc..

What development phase is rAAVrh74.MHCK7.DYSF.DV in?

rAAVrh74.MHCK7.DYSF.DV is in Phase 1.

Last reviewed 2026-04-19 · How we verify

rAAVrh74.MHCK7.DYSF.DV

Sarepta Therapeutics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	rAAVrh74.MHCK7.DYSF.DV
Sponsor	Sarepta Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related) (PHASE1)
rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

rAAVrh74.MHCK7.DYSF.DV CI brief — competitive landscape report
rAAVrh74.MHCK7.DYSF.DV updates RSS · CI watch RSS
Sarepta Therapeutics, Inc. portfolio CI